Chel Hun Choi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2490361/publications.pdf

Version: 2024-02-01

134	3,628	236925	155660
papers	citations	25 h-index	55 g-index

137	137	137	5472
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2017, 18, 1274-1284.	10.7	1,376
2	Single-Port Access Laparoscopic-Assisted Vaginal Hysterectomy: A Novel Method with a Wound Retractor and a Glove. Journal of Minimally Invasive Gynecology, 2009, 16, 450-453.	0.6	126
3	The prognostic significance of the SUVmax (maximum standardized uptake value for F-18) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 5 results. Gynecologic Oncology, 2009, 115, 65-68.	1.4	78
4	Meta-analysis of the effects of beta blocker on survival time in cancer patients. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1179-1188.	2.5	72
5	Comparison of laparoscopic and abdominal radical hysterectomy in early stage cervical cancer patients without adjuvant treatment: Ancillary analysis of a Korean Gynecologic Oncology Group Study (KGOG 1028). Gynecologic Oncology, 2019, 154, 547-553.	1.4	68
6	Prognostic factors and outcomes in endometrial stromal sarcoma with the 2009 FIGO staging system: A multicenter review of 114 cases. Gynecologic Oncology, 2014, 132, 70-75.	1.4	63
7	Patient-Derived Xenograft Models of Epithelial Ovarian Cancer for Preclinical Studies. Cancer Research and Treatment, 2017, 49, 915-926.	3.0	58
8	Tumor Suppressive Effects of Bromodomain-Containing Protein 7 (BRD7) in Epithelial Ovarian Carcinoma. Clinical Cancer Research, 2014, 20, 565-575.	7.0	56
9	Hypermethylation and loss of heterozygosity of tumor suppressor genes on chromosome 3p in cervical cancer. Cancer Letters, 2007, 255, 26-33.	7.2	51
10	Proton pump inhibitors enhance the effects of cytotoxic agents in chemoresistant epithelial ovarian carcinoma. Oncotarget, 2015, 6, 35040-35050.	1.8	48
11	Survival analysis of revised 2013 FIGO staging classification of epithelial ovarian cancer and comparison with previous FIGO staging classification. Obstetrics and Gynecology Science, 2015, 58, 124.	1.6	45
12	A Matched-Case Comparison to Explore the Role of Consolidation Chemotherapy After Concurrent Chemoradiation in Cervical Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 81, 1252-1257.	0.8	38
13	Prediction of survival outcomes in patients with epithelial ovarian cancer using machine learning methods. Journal of Gynecologic Oncology, 2019, 30, e65.	2.2	38
14	The anti-cancer effects of itraconazole in epithelial ovarian cancer. Scientific Reports, 2017, 7, 6552.	3.3	37
15	Angiotensin II type I receptor and miR-155 in endometrial cancers: Synergistic antiproliferative effects of anti-miR-155 and losartan on endometrial cancer cells. Gynecologic Oncology, 2012, 126, 124-131.	1.4	36
16	Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001. International Journal of Gynecological Cancer, 2022, 32, 93-100.	2.5	36
17	Phase II study of neoadjuvant chemotherapy with mitomycin-c, vincristine and cisplatin (MVC) in patients with stages IB2â€“IIB cervical carcinoma. Gynecologic Oncology, 2007, 104, 64-69.	1.4	35
18	Robotic Versus Laparoscopic Radical Hysterectomy in Cervical Cancer Patients: A Matched-Case Comparative Study. International Journal of Gynecological Cancer, 2014, 24, 1466-1473.	2.5	34

#	Article	IF	Citations
19	c-MET as a Potential Therapeutic Target in Ovarian Clear Cell Carcinoma. Scientific Reports, 2016, 6, 38502.	3.3	34
20	Perioperative administration of propranolol to women undergoing ovarian cancer surgery: A pilot study. Obstetrics and Gynecology Science, 2017, 60, 170.	1.6	33
21	Comparison of Laparoscopic-Assisted Radical Vaginal Hysterectomy and Laparoscopic Radical Hysterectomy in the Treatment of Cervical Cancer. Annals of Surgical Oncology, 2012, 19, 3839-3848.	1.5	31
22	Surgical Outcomes of a New Approach to Laparoscopic Myomectomy: Single-Port and Modified Suture Technique. Journal of Minimally Invasive Gynecology, 2014, 21, 580-585.	0.6	31
23	Interval between secondary cytoreductive surgery and adjuvant chemotherapy is not associated with survivals in patients with recurrent ovarian cancer. Journal of Ovarian Research, 2020, 13, 1.	3.0	31
24	Prognostic Value of Baseline Lymphocyte Count in Cervical Carcinoma Treated With Concurrent Chemoradiation. International Journal of Radiation Oncology Biology Physics, 2008, 71, 199-204.	0.8	30
25	Dual targeting of angiotensin receptors (AGTR1 and AGTR2) in epithelial ovarian carcinoma. Gynecologic Oncology, 2014, 135, 108-117.	1.4	29
26	Clinical outcomes of patients with clear cell and endometrioid ovarian cancer arising from endometriosis. Journal of Gynecologic Oncology, 2018, 29, e18.	2.2	29
27	Papillary serous carcinoma in ovaries of normal size: A clinicopathologic study of 20 cases and comparison with extraovarian peritoneal papillary serous carcinoma. Gynecologic Oncology, 2007, 105, 762-768.	1.4	28
28	Prognostic value of pretreatment hemoglobin level in patients with early cervical cancer. Obstetrics and Gynecology Science, 2014, 57, 28.	1.6	27
29	Anti-Tumor Effects of Wee1 Kinase Inhibitor with Radiotherapy in Human Cervical Cancer. Scientific Reports, 2019, 9, 15394.	3.3	27
30	Peritoneal Tuberculosis: A Retrospective Review of 20 Cases and Comparison With Primary Peritoneal Carcinoma. International Journal of Gynecological Cancer, 2010, 20, 798-803.	2.5	25
31	Proton Pump Inhibition Enhances the Cytotoxicity of Paclitaxel in Cervical Cancer. Cancer Research and Treatment, 2017, 49, 595-606.	3.0	24
32	Phase II Study of Consolidation Chemotherapy After Concurrent Chemoradiation in Cervical Cancer: Preliminary Results. International Journal of Radiation Oncology Biology Physics, 2007, 68, 817-822.	0.8	23
33	Direct inhibition of eIF4E reduced cell growth in endometrial adenocarcinoma. Journal of Cancer Research and Clinical Oncology, 2011, 137, 463-469.	2.5	23
34	Prognostic significance of VEGF expression in patients with bulky cervical carcinoma undergoing neoadjuvant chemotherapy. BMC Cancer, 2008, 8, 295.	2.6	22
35	Minimally invasive compared with open surgery in patients with borderline ovarian tumors. Gynecologic Oncology, 2017, 145, 508-512.	1.4	21
36	Biomarker-guided targeted therapy in platinum-resistant ovarian cancer (AMBITION; KGOG 3045): a multicentre, open-label, five-arm, uncontrolled, umbrella trial. Journal of Gynecologic Oncology, 2022, 33, .	2.2	21

#	Article	IF	Citations
37	Impact of lymphadenectomy on survival after recurrence in patients with advanced ovarian cancer without suspected lymph node metastasis. Gynecologic Oncology, 2016, 143, 252-257.	1.4	20
38	Ubiquitylation and degradation of adenomatous polyposis coli by MKRN1 enhances Wnt/Î²-catenin signaling. Oncogene, 2018, 37, 4273-4286.	5.9	20
39	Primary ovarian choriocarcinoma mimicking ectopic pregnancy. Obstetrics and Gynecology Science, 2014, 57, 330.	1.6	19
40	Surgical outcome prediction in patients with advanced ovarian cancer using computed tomography scans and intraoperative findings. Taiwanese Journal of Obstetrics and Gynecology, 2014, 53, 343-347.	1.3	19
41	Single-site robotic surgery in gynecologic cancer: a pilot study. Journal of Gynecologic Oncology, 2015, 26, 62.	2.2	19
42	Prognostic value of ADC quantification for clinical outcome in uterine cervical cancer treated with concurrent chemoradiotherapy. European Radiology, 2019, 29, 6236-6244.	4.5	19
43	Prognostic Model for Survival and Recurrence in Patients with Early-Stage Cervical Cancer: A Korean Gynecologic Oncology Group Study (KGOG 1028). Cancer Research and Treatment, 2020, 52, 320-333.	3.0	19
44	Cervical conization before primary radical hysterectomy has a protective effect on disease recurrence in early cervical cancer: A two-center matched cohort study according to surgical approach. Gynecologic Oncology, 2022, 164, 535-542.	1.4	19
45	Extrauterine epithelioid trophoblastic tumor in hysterectomized woman. Obstetrics and Gynecology Science, 2017, 60, 124.	1.6	18
46	Overexpression of annexin A4 is associated with chemoresistance in papillary serous adenocarcinoma of the ovary. Human Pathology, 2013, 44, 1017-1023.	2.0	17
47	Pancreatic adenocarcinoma up-regulated factor expression is associated with disease-specific survival in cervical cancer patients. Human Pathology, 2015, 46, 884-893.	2.0	17
48	Uterine Fibroids: Correlation of T2 Signal Intensity with Semiquantitative Perfusion MR Parameters in Patients Screened for MR-guided High-Intensity Focused Ultrasound Ablation. Radiology, 2016, 278, 925-935.	7.3	17
49	An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3045), AMBITION. Japanese Journal of Clinical Oncology, 2019, 49, 789-792.	1.3	17
50	Prognostic significance of USP10 and p14ARF expression in patients with colorectal cancer. Pathology Research and Practice, 2020, 216, 152988.	2.3	17
51	Chemoradiotherapy response prediction model by proteomic expressional profiling in patients with locally advanced cervical cancer. Gynecologic Oncology, 2020, 157, 437-443.	1.4	17
52	A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01). Journal of Gynecologic Oncology, 2021, 32, e31.	2.2	17
53	Reduced expression of FILIP1L, a novel WNT pathway inhibitor, is associated with poor survival, progression and chemoresistance in ovarian cancer. Oncotarget, 2016, 7, 77052-77070.	1.8	17
54	Postoperative outcomes of MR-invisible stage IB1 cervical cancer. American Journal of Obstetrics and Gynecology, 2014, 211, 168.e1-168.e7.	1.3	16

#	Article	IF	Citations
55	Perioperative Outcomes of Radical Trachelectomy in Early-Stage Cervical Cancer: Vaginal Versus Laparoscopic Approaches. International Journal of Gynecological Cancer, 2015, 25, 1051-1057.	2.5	16
56	Pharmacogenomic analysis of patient-derived tumor cells in gynecologic cancers. Genome Biology, 2019, 20, 253.	8.8	16
57	Safety and efficacy of aprepitant, ramosetron, and dexamethasone for chemotherapy-induced nausea and vomiting in patients with ovarian cancer treated with paclitaxel/carboplatin. Supportive Care in Cancer, 2014, 22, 1181-1187.	2.2	15
58	Laparoendoscopic single-site (LESS) myomectomy: characteristics of the appropriate myoma. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2014, 175, 58-61.	1.1	15
59	CDK7 is a reliable prognostic factor and novel therapeutic target in epithelial ovarian cancer. Gynecologic Oncology, 2020, 156, 211-221.	1.4	15
60	A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D. Journal of Gynecologic Oncology, 2019, 30, e112.	2.2	15
61	Phase II study of belotecan, a camptothecin analogue, in combination with carboplatin for the treatment of recurrent ovarian cancer. Cancer, 2011, 117, 2104-2111.	4.1	14
62	Timing and patterns of recurrence in epithelial ovarian cancer patients with no gross residual disease after primary debulking surgery. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2016, 56, 639-647.	1.0	14
63	A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physicianâ€™s choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA). International Journal of Gynecological Cancer, 2020, 30, 1239-1242.	2.5	14
64	Phase I Study of a B Cell-Based and Monocyte-Based Immunotherapeutic Vaccine, BVAC-C in Human Papillomavirus Type 16- or 18-Positive Recurrent Cervical Cancer. Journal of Clinical Medicine, 2020, 9, 147.	2.4	14
65	Surgical manual of the Korean Gynecologic Oncology Group: classification of hysterectomy and lymphadenectomy. Journal of Gynecologic Oncology, 2017, 28, e5.	2.2	13
66	Dynamin 2 Inhibitors as Novel Therapeutic Agents Against Cervical Cancer Cells. Anticancer Research, 2016, 36, 6381-6388.	1.1	13
67	Impact of Angiotensin Receptor Blockers, Beta Blockers, Calcium Channel Blockers and Thiazide Diuretics on Survival of Ovarian Cancer Patients. Cancer Research and Treatment, 2020, 52, 645-654.	3.0	13
68	Prognostic significance of pâ€STAT3 in patients with bulky cervical carcinoma undergoing neoadjuvant chemotherapy. Journal of Obstetrics and Gynaecology Research, 2010, 36, 304-310.	1.3	11
69	Borderline ovarian tumor in women aged â‰¥65 years: impact on recurrence and survival. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2015, 184, 38-42.	1.1	11
70	Dual loss of USP10 and p14ARF protein expression is associated with poor prognosis in patients with small intestinal adenocarcinoma. Tumor Biology, 2018, 40, 101042831880867.	1.8	10
71	The role of appendectomy in patients with mucinous borderline ovarian tumors. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2018, 229, 112-116.	1.1	10
72	Comparison between laparoendoscopic single-site and conventional laparoscopic surgery in mature cystic teratoma of the ovary. Gynecology and Minimally Invasive Therapy, 2019, 8, 155.	0.9	10

#	Article	IF	Citations
73	Nomograms Predicting Platinum Sensitivity, Progression-Free Survival, and Overall Survival Using Pretreatment Complete Blood Cell Counts in Epithelial Ovarian Cancer. Cancer Research and Treatment, 2017, 49, 635-642.	3.0	10
74	Analysis of clinical outcomes of patients with adenoid cystic carcinoma of Bartholin glands. International Journal of Clinical and Experimental Pathology, 2015, 8, 5688-94.	0.5	10
75	Clinical significance of pmTOR expression in endometrioid endometrial carcinoma. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2010, 153, 207-210.	1.1	9
76	Comparison of survival outcomes after recurrence detected by cancer antigen 125 elevation versus imaging study in epithelial ovarian cancer. Journal of Gynecologic Oncology, 2016, 27, e46.	2.2	9
77	Prognostic significance of normal-sized ovary in advanced serous epithelial ovarian cancer. Journal of Gynecologic Oncology, 2018, 29, e13.	2.2	9
78	Pretreatment Lymph Node Metastasis as a Prognostic Significance in Cervical Cancer: Comparison between Disease Status. Cancer Research and Treatment, 2020, 52, 516-523.	3.0	9
79	Safety and efficacy study of laparoscopic or robotic radical surgery using an endoscopic stapler for inhibiting tumour spillage of cervical malignant neoplasms evaluating survival (SOLUTION): a multi-centre, open-label, single-arm, phase II trial protocol. BMC Cancer, 2022, 22, 331.	2.6	9
80	Expression of CD44 adhesion molecules on human placentae. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2006, 128, 243-247.	1.1	8
81	Long-term outcomes of magnetic resonance imaging-invisible endometrial cancer. Journal of Gynecologic Oncology, 2016, 27, e38.	2.2	8
82	Clinical characteristics and outcomes of placental site trophoblastic tumor: experience of single institution in Korea. Obstetrics and Gynecology Science, 2018, 61, 319.	1.6	8
83	Real-World Experience of Olaparib Maintenance in High-Grade Serous Recurrent Ovarian Cancer Patients with BRCA1/2 Mutation: A Korean Multicenter Study. Journal of Clinical Medicine, 2019, 8, 1920.	2.4	8
84	Optimal cutoff age for predicting prognosis associated with serous epithelial ovarian cancer: what is the best age cutoff?. Journal of Gynecologic Oncology, 2019, 30, e11.	2.2	8
85	Prognostic Significance of Tumor Regression Rate during Concurrent Chemoradiotherapy in Locally Advanced Cervix Cancer: Analysis by Radiation Phase and Histologic Type. Journal of Clinical Medicine, 2020, 9, 3471.	2.4	8
86	Vulvar epithelioid sarcoma: A case report with literature review. Taiwanese Journal of Obstetrics and Gynecology, 2021, 60, 132-135.	1.3	8
87	Machine Learning Models to Predict Survival Outcomes According to the Surgical Approach of Primary Radical Hysterectomy in Patients with Early Cervical Cancer. Cancers, 2021, 13, 3709.	3.7	8
88	Prevalence and oncologic outcomes of BRCA1/2 mutation and variant of unknown significance in epithelial ovarian carcinoma patients in Korea. Obstetrics and Gynecology Science, 2019, 62, 411.	1.6	7
89	A multicenter phase II randomized trial of durvalumab (D) versus physicianâ€™s choice chemotherapy (PCC) in patients (pts) with recurrent ovarian clear cell adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3).. Journal of Clinical Oncology, 2022, 40, 5565-5565.	1.6	7
90	A prospective comparative study of cosmetic satisfaction for three different surgical approaches. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2015, 190, 48-51.	1.1	6

#	Article	IF	Citations
91	Feasibility of laparoscopic cytoreduction in patients with localized recurrent epithelial ovarian cancer. Journal of Gynecologic Oncology, 2016, 27, e24.	2.2	6
92	Genomic Network-Based Analysis Reveals Pancreatic Adenocarcinoma Up-Regulating Factor-Related Prognostic Markers in Cervical Carcinoma. Frontiers in Oncology, 2018, 8, 465.	2.8	6
93	Discrepancy between Cytology and Histology in Cervical Cancer Screening: a Multicenter Retrospective Study (KGOG 1040). Journal of Korean Medical Science, 2021, 36, e164.	2.5	6
94	Prevalence and clinical characterization of BRCA1 and BRCA2 mutations in Korean patients with epithelial ovarian cancer. Cancer Science, 2021, 112, 5055-5067.	3.9	6
95	Combination of a pulmonary recruitment maneuver and intraperitoneal bupivacaine for the reduction of postoperative shoulder pain in gynecologic laparoscopy: a randomized, controlled trial. Obstetrics and Gynecology Science, 2020, 63, 187-194.	1.6	6
96	The effect of coexisting squamous cell lesions on prognosis in patients with cervical adenocarcinoma in situ. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2015, 190, 26-30.	1.1	5
97	Prognostic factors for recurrence and survival in uterine leiomyosarcoma: Korean single center experience with 50 cases. Obstetrics and Gynecology Science, 2019, 62, 103.	1.6	5
98	Triplet chemotherapy vs doublet chemotherapy plus bevacizumab in metastatic, recurrent, and persistent cervical cancer. Current Problems in Cancer, 2020, 44, 100557.	2.0	5
99	Effect of Waiting Time from Pathological Diagnosis to Definitive Concurrent Chemoradiation for Cervical Cancer on Overall Survival. Cancer Research and Treatment, 2022, 54, 245-252.	3.0	5
100	Long-term outcomes of single-port laparoscopic myomectomy using a modified suture technique. Obstetrics and Gynecology Science, 2020, 63, 164-172.	1.6	5
101	Is laparoendoscopic single-site surgery (LESS) retroperitoneal hysterectomy feasible?: Surgical outcomes of the initial 27 cases. Taiwanese Journal of Obstetrics and Gynecology, 2015, 54, 150-154.	1.3	4
102	Retroperitoneal Approach in Single-Port Laparoscopic Hysterectomy. Journal of the Society of Laparoendoscopic Surgeons, 2016, 20, e2016.00001.	1.1	4
103	Women with double primary cancers of the colorectum and endometrium: do they have Lynch syndrome?. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2016, 199, 208-212.	1.1	4
104	Retrospective study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancer. Obstetrics and Gynecology Science, 2018, 61, 352.	1.6	4
105	Effectiveness of adjuvant treatment for morcellated, International Federation of Gynecology and Obstetrics stage I uterine leiomyosarcoma: A Korean multicenter study. Journal of Obstetrics and Gynaecology Research, 2019, 46, 337-346.	1.3	4
106	Feasibility of Single-Port Access (SPA) Laparoscopy for Large Ovarian Tumor Suspected to Be Borderline Ovarian Tumor. Frontiers in Oncology, 2020, 10, 583515.	2.8	4
107	Comparison of Laparoscopy and Laparotomy for Para-Aortic Lymphadenectomy in Women With Presumed Stage Iâ€“II High-Risk Endometrial Cancer. Frontiers in Oncology, 2020, 10, 451.	2.8	4
108	Metabolic syndrome and persistent cervical human papillomavirus infection. Gynecologic Oncology, 2021, 161, 559-564.	1.4	4

#	Article	IF	Citations
109	Development and Validation of Ovarian Symptom Index-18 and Neurotoxicity-4 for Korean Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Cancer Research and Treatment, 2019, 51, 112-118.	3.0	4
110	Laparoendoscopic single-site radical hysterectomy for early stage cervical cancer. Obstetrics and Gynecology Science, 2017, 60, 110.	1.6	3
111	Significance of serum CA125 level in surgically resected cervical adenocarcinoma with adverse features. Journal of Gynecologic Oncology, 2021, 32, e72.	2.2	3
112	Molecular Signature for Lymphatic Invasion Associated with Survival of Epithelial Ovarian Cancer. Cancer Research and Treatment, 2018, 50, 461-473.	3.0	3
113	Utility of 3T MRI in Women with IB1 Cervical Cancer in Determining the Necessity of Less Invasive Surgery. Cancers, 2022, 14, 224.	3.7	3
114	Clinical outcome of pulmonary lymphangitic carcinomatosis in gynecologic malignancy: A single-institution experience. Taiwanese Journal of Obstetrics and Gynecology, 2022, 61, 333-338.	1.3	3
115	Prognostic Significance of HER3 Expression in Patients with Cervical Cancer. Cancers, 2022, 14, 2139.	3.7	3
116	Robotic high para-aortic lymph node dissection with high port placement using same port for pelvic surgery in gynecologic cancer patients. Journal of Gynecologic Oncology, 2015, 26, 222.	2.2	2
117	The Prognostic Model of Pre-Treatment Complete Blood Count (CBC) for Recurrence in Early Cervical Cancer. Journal of Clinical Medicine, 2020, 9, 2960.	2.4	2
118	Identification of Candidate Genes Associated with Susceptibility to Ovarian Clear Cell Adenocarcinoma Using cis-eQTL Analysis. Journal of Clinical Medicine, 2020, 9, 1137.	2.4	2
119	Minimally-Invasive Versus Abdominal Hysterectomy for Endometrial Carcinoma With Glandular or Stromal Invasion of Cervix. Frontiers in Oncology, 2021, 11, 670214.	2.8	2
120	An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer (KGOG 3045, AMBITION).. Journal of Clinical Oncology, 2021, 39, 5520-5520.	1.6	2
121	Phase IIa study of BVAC-C in HPV type 16 or 18 positive recurrent cervical carcinoma.. Journal of Clinical Oncology, 2021, 39, 5512-5512.	1.6	2
122	Early Metabolic Response Assessed Using 18F-FDG-PET/CT for Image-Guided Intracavitary Brachytherapy Can Better Predict Treatment Outcomes in Patients with Cervical Cancer. Cancer Research and Treatment, 2021, 53, 803-812.	3.0	2
123	Validation of Potential Protein Markers Predicting Chemoradioresistance in Early Cervical Cancer by Immunohistochemistry. Frontiers in Oncology, 2021, 11, 665595.	2.8	2
124	Prognostic Relevance of BRCA1 Expression in Survival of Patients With Cervical Cancer. Frontiers in Oncology, 2021, 11, 770103.	2.8	2
125	Impact of no residual disease on postoperative computed tomography on survival in patients with optimally debulked advanced high-grade serous ovarian cancer during upfront surgery. Gynecologic Oncology, 2022, , .	1.4	2
126	Single-port access (SPA) laparoscopic myomectomy with uterine artery ligation via a retroperitoneal approach is feasible in women with large uterine leiomyoma. Taiwanese Journal of Obstetrics and Gynecology, 2021, 60, 752-757.	1.3	1

#	Article	IF	Citations
127	Comparative performance of various human papillomavirus assays available in Korea for detecting cervical intraepithelial neoplasia. Journal of Obstetrics and Gynaecology Research, 2021, , .	1.3	1
128	Interim analysis from a phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer: APGOT-ov4/OPEB-01.. Journal of Clinical Oncology, 2022, 40, e17579-e17579.	1.6	1
129	Effective thermal destruction of residual tubal epithelium using an advanced sealing device in opportunistic salpingectomy: A randomized trial. Gynecology and Minimally Invasive Therapy, 2017, 6, 108-112.	0.9	0
130	Neoadjuvant chemotherapy with mitomycin-C, vincristine and cisplatin (MVC) for patients with loco-regionally advanced cervical carcinoma. Korean Journal of Gynecologic Oncology, 2006, 17, 15.	0.1	0
131	Superior vena cava syndrome secondary to hickman catheter in the advanced cervical cancer patient treated with concurrent chemoradiotherapy: A case report. Korean Journal of Obstetrics & Gynecology, 2012, 55, 761.	0.1	0
132	Prognostic model for disease-free survival, lymphatic and/or hematogenous recurrence, in patients with early stage cervical cancer treated with radical hysterectomy: A Korean Gynecologic Oncology Group Study.. Journal of Clinical Oncology, 2016, 34, e17000-e17000.	1.6	0
133	Effect of postoperative adjuvant treatment in the therapeutic management of stage I, morcellated uterine leiomyosarcoma: A Korean multicenter study.. Journal of Clinical Oncology, 2019, 37, e17106-e17106.	1.6	0
134	Survival Effects of Cytoreductive Surgery for Refractory Patients after Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer. Yonsei Medical Journal, 2020, 61, 935.	2.2	0